Etrolizumab for ulcerative colitis: the new kid on the block?

  title={Etrolizumab for ulcerative colitis: the new kid on the block?},
  author={Jitin Makker and Daniel W. Hommes},
  journal={Expert Opinion on Biological Therapy},
  pages={567 - 572}
ABSTRACT Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. Currently approved therapies include prednisone, TNF antagonists and anti-metabolites which often are ineffective and have frequent adverse effects. Consequently, UC patients are always at risk for developing serious complications that affect their quality of life. Therefore, new treatment options are required. Areas covered: This article discusses etrolizumab, its mechanism and the… 
Monoclonal Antibodies for Immune System-Mediated Diseases
This chapter aims to give a general introduction to the immune diseases and inflammatory pathways being targeted by mAbs, focusing on those that are approved or in late-stage clinical development, and to have a better understanding of the mechanism of action.
Integrins in T Cell Physiology
From the thymus to the peripheral lymph nodes, integrin-mediated interactions with neighbor cells and the extracellular matrix tune T cell behavior by organizing cytoskeletal remodeling and
Efficacy and safety of stellate ganglion block in chronic ulcerative colitis
The application of stellate ganglion block effectively improves treatment efficacy in chronic ulcerative colitis, relieves clinical symptoms in patients, and reduces the level of inflammatory factors.
Integrins as Therapeutic Targets: Successes and Cancers
The current developments in integrin therapeutics, especially in cancer, are examined, and the health economic implications of these developments are commented on.


New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified, and vedolizumab belongs to a new class of agents that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway.
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Ulcerative Colitis: Update on Medical Management
The recent publication of the SCENIC consensus statement on surveillance and management of Dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia and new biologics, including those targeting the Janus tyrosine kinase (JAK) pathway are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies.
New therapies for inflammatory bowel disease: from the bench to the bedside
This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD.
Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Vedolizumab was significantly superior to placebo for induction of remission, clinical response, and endoscopic remission and prevention of relapse, and the overall quality of the evidence supporting the outcomes was high.
[Medical therapy in ulcerative colitis].
In patients with moderate or severe ulcerative colitis, glucocorticoids which may be given in conjunction with SASP or 5-ASA are beneficial in producing remission, and early surgical consultation is necessary in severely ill patients.
Clinical use of anti-TNF therapy and increased risk of infections
A literature review of the published data on the risk of bacterial, viral, fungal, and parasitic infections associated with anti-TNF therapy was performed and the clinical presentation, diagnostic tests, management, and prevention of opportunistic infections in patients receiving anti- TNF therapy were reviewed.
The Yin and Yang of Immunomodulatory Biologics: Assessing the Delicate Balance between Benefit and Risk
The nonclinical safety testing strategy for an immunomodulatory biologic should be custom tailored to interrogate the biology of the immunologic target in order to best assess potential clinical risk.
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Etrolizumab is well tolerated in moderate to severe UC, and the duration of β7 receptor full occupancy was dose related, and headache was the most common adverse event.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.